[go: up one dir, main page]

MX2016014926A - Dominios variables de inmunoglobulina mejorados. - Google Patents

Dominios variables de inmunoglobulina mejorados.

Info

Publication number
MX2016014926A
MX2016014926A MX2016014926A MX2016014926A MX2016014926A MX 2016014926 A MX2016014926 A MX 2016014926A MX 2016014926 A MX2016014926 A MX 2016014926A MX 2016014926 A MX2016014926 A MX 2016014926A MX 2016014926 A MX2016014926 A MX 2016014926A
Authority
MX
Mexico
Prior art keywords
amino acid
acid residue
variable domains
immunoglobulin variable
improved
Prior art date
Application number
MX2016014926A
Other languages
English (en)
Other versions
MX383560B (es
Inventor
Buyse Marie-Ange
Button Carlo
Original Assignee
Ablynx Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ablynx Nv filed Critical Ablynx Nv
Publication of MX2016014926A publication Critical patent/MX2016014926A/es
Publication of MX383560B publication Critical patent/MX383560B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Se describe el dominio VH, en el cual: (i) el residuo de aminoácido en la posición 112 es uno de K o Q; y/o (ii) el residuo de aminoácido en la posición en la posición 89 es T; y/o (iii) el residuo de aminoácido en la posición 89 es L y el residuo de aminoácido en la posición 110 es uno de K o Q; y (iv) en cada uno de los casos (i) a (iii), el aminoácido en la posición 11 es de manera preferente V; y en el cual el dominio VH contiene una extensión C-terminal (X)n en el cual n es uno 1 a 10, de manera preferente 1 a 5, tal como 1, 2, 3, 4, o 5 (y de manera preferente 1 o 2, tal como 1); y cada X es un residuo de aminoácido (de manera preferente de origen natural) que se elige independientemente y de manera preferente se elige independientemente del grupo que consiste de alanina (A), glicina (G), valina (V), leucina (L) o isoleucina (I).
MX2016014926A 2014-05-16 2015-05-13 Dominios variables de inmunoglobulina mejorados. MX383560B (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201461994552P 2014-05-16 2014-05-16
US201461014015P 2014-06-18 2014-06-18
US201462014015P 2014-06-18 2014-06-18
US201462040167P 2014-08-21 2014-08-21
US201462047560P 2014-09-08 2014-09-08
US201562133600P 2015-03-16 2015-03-16
PCT/EP2015/060643 WO2015173325A2 (en) 2014-05-16 2015-05-13 Improved immunoglobulin variable domains

Publications (2)

Publication Number Publication Date
MX2016014926A true MX2016014926A (es) 2017-05-09
MX383560B MX383560B (es) 2025-03-14

Family

ID=91193230

Family Applications (4)

Application Number Title Priority Date Filing Date
MX2016014926A MX383560B (es) 2014-05-16 2015-05-13 Dominios variables de inmunoglobulina mejorados.
MX2023010731A MX2023010731A (es) 2014-05-16 2016-11-14 Dominios variables de inmunoglobulina mejorados.
MX2021007020A MX2021007020A (es) 2014-05-16 2016-11-14 Dominios variables de inmunoglobulina mejorados.
MX2018007581A MX2018007581A (es) 2014-05-16 2016-11-14 Dominios variables de inmunoglobulina mejorados.

Family Applications After (3)

Application Number Title Priority Date Filing Date
MX2023010731A MX2023010731A (es) 2014-05-16 2016-11-14 Dominios variables de inmunoglobulina mejorados.
MX2021007020A MX2021007020A (es) 2014-05-16 2016-11-14 Dominios variables de inmunoglobulina mejorados.
MX2018007581A MX2018007581A (es) 2014-05-16 2016-11-14 Dominios variables de inmunoglobulina mejorados.

Country Status (24)

Country Link
US (10) US12180268B2 (es)
EP (4) EP3143042B1 (es)
JP (6) JP7325928B2 (es)
KR (5) KR20170002645A (es)
CN (3) CN109053885A (es)
AU (6) AU2015261536B2 (es)
BR (2) BR122018009619B1 (es)
CA (2) CA2948076A1 (es)
DK (2) DK3143042T3 (es)
ES (2) ES2912069T3 (es)
HR (2) HRP20220400T1 (es)
HU (2) HUE050007T2 (es)
IL (6) IL295534B2 (es)
LT (2) LT3248986T (es)
MX (4) MX383560B (es)
PH (1) PH12016502282B1 (es)
PL (2) PL3143042T3 (es)
PT (2) PT3248986T (es)
RS (2) RS60717B1 (es)
RU (1) RU2746738C2 (es)
SG (3) SG11201609162SA (es)
SI (2) SI3143042T1 (es)
WO (1) WO2015173325A2 (es)
ZA (5) ZA201607587B (es)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11644471B2 (en) 2010-09-30 2023-05-09 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
SG10201605048XA (en) * 2011-06-23 2016-07-28 Ablynx Nv Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
KR20250099289A (ko) 2014-05-16 2025-07-01 아블린쓰 엔.브이. 개선된 면역글로불린 가변 도메인
AU2015261536B2 (en) 2014-05-16 2020-05-07 Ablynx Nv Improved immunoglobulin variable domains
CN114478753A (zh) 2015-01-21 2022-05-13 英伊布里克斯公司 非免疫原性单结构域抗体
JP7403224B2 (ja) 2015-11-12 2023-12-22 アブリンクス エン．ヴェー． 改良されたｐ２ｘ７受容体結合剤およびこれを含むポリペプチド
NO2768984T3 (es) * 2015-11-12 2018-06-09
RS62857B1 (sr) 2015-11-13 2022-02-28 Ablynx Nv Unapređeni varijabilni domeni imunoglobulina koji vezuju serumski albumin
EA038179B1 (ru) * 2015-11-18 2021-07-20 Мерк Шарп И Доум Корп. Ctla4-связывающие вещества
RU2755724C2 (ru) 2015-11-18 2021-09-20 Мерк Шарп И Доум Корп. Pd1/ctla4-связывающие вещества
JP7046804B2 (ja) * 2015-11-18 2022-04-04 アブリンクス エン．ヴェー． 改良された血清アルブミン結合剤
UA121914C2 (uk) 2015-11-18 2020-08-10 Мерк Шарп І Доум Корп. Молекула, що зв'язує pd1 і lag3
EP3414268A1 (en) 2016-02-12 2018-12-19 Ablynx NV Method for the production of immunoglobulin single variable domains
CN107400166A (zh) * 2016-05-19 2017-11-28 苏州康宁杰瑞生物科技有限公司 针对ctla4的单域抗体及其衍生蛋白
US20190195866A1 (en) 2016-06-23 2019-06-27 Ablynx N.V. Improved pharmacokinetic assays for immunoglobulin single variable domains
CN117700549A (zh) 2016-11-16 2024-03-15 埃博灵克斯股份有限公司 能够结合CD123和TCRα/β的T细胞募集多肽
KR20230061582A (ko) 2016-12-07 2023-05-08 아블린쓰 엔.브이. 개선된 혈청 알부민 결합성 면역글로불린 단일 가변 도메인
SG10202108973SA (en) 2017-01-17 2021-09-29 Ablynx Nv Improved serum albumin binders
CN117285623A (zh) 2017-01-17 2023-12-26 埃博灵克斯股份有限公司 改进的血清白蛋白结合物
RS66191B1 (sr) 2017-06-02 2024-12-31 Merck Patent Gmbh Imunoglobulini koji vezuju adamts
WO2019016237A1 (en) 2017-07-19 2019-01-24 Vib Vzw AGENTS FOR CONNECTING TO SERUM ALBUMIN
US11873347B2 (en) 2017-10-31 2024-01-16 Vib Vzw Antigen-binding chimeric proteins and methods and uses thereof
US12465640B2 (en) 2019-02-25 2025-11-11 The University Of Chicago Methods and compositions for treating inflammatory and autoimmune conditions with ECM-affinity peptides linked to anti-inflammatory agents
WO2020221888A1 (en) 2019-04-30 2020-11-05 Vib Vzw Cystic fibrosis transmembrane conductance regulator stabilizing agents
WO2021105438A1 (en) 2019-11-27 2021-06-03 Vib Vzw Positive allosteric modulators of the calcium-sensing receptor
MX2022006881A (es) 2019-12-06 2022-07-11 Ablynx Nv Polipeptidos que comprenden dominios variables unicos de inmunoglobulina dirigidos a tnf alfa y ox40l.
WO2021110816A1 (en) 2019-12-06 2021-06-10 Ablynx Nv POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING TNFα AND IL-23
AR120698A1 (es) 2019-12-09 2022-03-09 Ablynx Nv Polipéptidos que comprenden dominios variables únicos de inmunoglobulina que se dirigen a il-13 y tslp
TWI861302B (zh) 2019-12-09 2024-11-11 比利時商艾伯霖克斯公司 包含靶向il-13及tslp之免疫球蛋白單可變域的多肽
US20240027467A1 (en) 2019-12-20 2024-01-25 Vib Vzw Nanobody Exchange Chromatography
WO2021156490A2 (en) 2020-02-06 2021-08-12 Vib Vzw Corona virus binders
EP4110794A1 (en) 2020-02-25 2023-01-04 Vib Vzw Leucine-rich repeat kinase 2 allosteric modulators
CA3175873A1 (en) 2020-03-30 2021-10-07 Ablynx Nv Method for the production and purification of multivalent immunoglobulin single variable domains
WO2022003156A1 (en) 2020-07-02 2022-01-06 Oncurious Nv Ccr8 non-blocking binders
US20230272094A1 (en) * 2020-08-05 2023-08-31 Synthekine, Inc. Il2rb/il2rg synthetic cytokines
TW202229338A (zh) 2020-09-25 2022-08-01 比利時商艾伯霖克斯公司 包含靶向ｉｌ－１３和ｏｘ４０ｌ的免疫球蛋白單可變結構域的多肽
WO2022117569A1 (en) 2020-12-02 2022-06-09 Oncurious Nv A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer
WO2022117572A2 (en) 2020-12-02 2022-06-09 Oncurious Nv An ltbr agonist in combination therapy against cancer
PH12023500013A1 (en) 2020-12-04 2024-03-11 Tidal Therapeutics Inc Ionizable cationic lipids and lipi nanoparticles, and methods of synthesis and use thereof
TW202239763A (zh) 2020-12-18 2022-10-16 比利時商艾伯霖克斯公司 包含靶向ＩＬ－６和ＴＮＦ－α的免疫球蛋白單可變結構域的多肽
MX2023007299A (es) 2020-12-18 2023-07-04 Ablynx Nv Polipeptidos de reclutamiento de celulas t basados en la reactividad de tcr alfa/beta.
AU2021399955A1 (en) 2020-12-18 2023-08-03 Ablynx Nv Polypeptides comprising immunoglobulin single variable domains targeting glypican-3 and t cell receptor
GB202020502D0 (en) 2020-12-23 2021-02-03 Vib Vzw Antibody composistion for treatment of corona virus infection
CN117794566A (zh) 2021-02-05 2024-03-29 Vib研究所 沙贝病毒结合剂
AU2022216460A1 (en) 2021-02-05 2023-09-21 Universiteit Gent Sarbecovirus binders
US20250263490A1 (en) 2021-02-19 2025-08-21 Vib Vzw Cation-Independent Mannose-6-Phosphate Receptor Binders
CN117043184A (zh) * 2021-04-01 2023-11-10 南京再明医药有限公司 抗人血清白蛋白（hsa）的纳米抗体及其应用
WO2023016828A2 (en) 2021-07-30 2023-02-16 Vib Vzw Cation-independent mannose-6-phosphate receptor binders for targeted protein degradation
TW202330596A (zh) * 2021-11-29 2023-08-01 大陸商江蘇恆瑞醫藥股份有限公司 經修飾的蛋白或多肽
EP4448574A1 (en) 2021-12-17 2024-10-23 Ablynx N.V. Polypeptides comprising immunoglobulin single variable domains targeting tcralphabeta, cd33 and cd123
WO2023135198A1 (en) 2022-01-12 2023-07-20 Vib Vzw Human ntcp binders for therapeutic use and liver-specific targeted delivery
EP4508082A1 (en) 2022-04-13 2025-02-19 Vib Vzw An ltbr agonist in combination therapy against cancer
AU2023265474A1 (en) 2022-05-06 2024-10-31 Numab Therapeutics AG Antibody variable domains and antibodies having decreased immunogenicity
EP4273162A1 (en) * 2022-05-06 2023-11-08 Numab Therapeutics AG Antibody variable domains and antibodies having decreased immunogenicity
WO2023222825A1 (en) 2022-05-18 2023-11-23 Vib Vzw Sarbecovirus spike s2 subunit binders
EP4536627A1 (en) 2022-06-08 2025-04-16 Tidal Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof
AU2023290487A1 (en) 2022-06-14 2025-01-30 Ablynx Nv Immunoglobulin single variable domains targeting t cell receptor
AU2023313033A1 (en) 2022-07-27 2025-03-13 Ablynx Nv Polypeptides binding to a specific epitope of the neonatal fc receptor
EP4594348A1 (en) 2022-09-27 2025-08-06 Vib Vzw Antivirals against human parainfluenza virus
WO2024083843A1 (en) 2022-10-18 2024-04-25 Confo Therapeutics N.V. Amino acid sequences directed against the melanocortin 4 receptor and polypeptides comprising the same for the treatment of mc4r-related diseases and disorders
CN120380024A (zh) 2022-12-21 2025-07-25 建新公司 抗pd-1×4-1bb结合蛋白
US20240415974A1 (en) 2022-12-23 2024-12-19 Ablynx N.V. Protein-based conjugation carriers
CN120529914A (zh) 2023-01-09 2025-08-22 奥德赛治疗股份有限公司 抗tnfr2抗原结合蛋白及其用途
CN121013866A (zh) 2023-02-10 2025-11-25 阿穆尼克斯制药公司 靶向前列腺特异性膜抗原（psma）的组合物及其制备和使用方法
KR20250151445A (ko) 2023-02-17 2025-10-21 아블린쓰 엔.브이. 신생아 fc 수용체에 결합하는 폴리펩티드
WO2024175787A1 (en) 2023-02-24 2024-08-29 Vrije Universiteit Brussel Anti-inflammatory pannexin 1 channel inhibitors
CN121263437A (zh) 2023-03-14 2026-01-02 奥德赛治疗股份有限公司 抗cd25抗原结合蛋白及其用途
WO2024208816A1 (en) 2023-04-03 2024-10-10 Vib Vzw Blood-brain barrier crossing antibodies
AU2024267410A1 (en) 2023-05-08 2026-01-08 Sanofi Glycosylation of immunoglobulin single variable domains
AR132699A1 (es) 2023-05-17 2025-07-23 Odyssey Therapeutics Inc Anticuerpos de dominio único modificados
WO2024261235A1 (en) 2023-06-22 2024-12-26 Ablynx Nv Chimeric proteins for modulating cytokine receptor activity
AU2024308381A1 (en) 2023-06-29 2025-11-20 Odyssey Therapeutics, Inc. Anti-trailr2 antigen-binding proteins and uses thereof
AR133188A1 (es) 2023-07-05 2025-09-03 Ablynx Nv ANTAGONISTAS DE FcRn MEJORADOS PARA EL TRATAMIENTO DE ENFERMEDADES Y TRASTORNOS RELACIONADOS CON IgG
TW202525843A (zh) 2023-09-04 2025-07-01 法商賽諾菲公司 用於治療表現磷脂醯肌醇蛋白聚糖-3之腫瘤的多肽
TW202532432A (zh) 2023-09-22 2025-08-16 比利時商艾伯霖克斯公司 二及多價白蛋白結合劑
TW202530265A (zh) 2023-10-13 2025-08-01 美商奧迪希治療公司 抗cdh17抗原結合蛋白及其用途
AR134267A1 (es) 2023-11-08 2025-12-17 Sanofi Sa Degradador lisosómico basado en cd25 y usos del mismo
WO2025109176A1 (en) 2023-11-22 2025-05-30 Exevir Bio Bv Optimized sarbecovirus spike s2 subunit binders and compositions comprising the same
WO2025114529A1 (en) 2023-12-01 2025-06-05 Ablynx Nv Multispecific antibodies recognising human serum albumin, tcr and a tumor antigen recognising moiety
WO2025125577A1 (en) 2023-12-14 2025-06-19 Vib Vzw Antibodies against influenza b virus
WO2025133166A1 (en) 2023-12-22 2025-06-26 Ablynx Nv Protein-based carriers for site-specific amine conjugation
TW202543670A (zh) 2023-12-22 2025-11-16 比利時商艾伯霖克斯公司 用於核內投予之基於蛋白質的接合載劑
TW202543581A (zh) 2024-02-12 2025-11-16 美商艾伊拉醫療公司 遞送組成物
WO2025181155A1 (en) 2024-02-26 2025-09-04 Vib Vzw Human beta-glucocerebrosidase binders and uses thereof
WO2025217240A1 (en) 2024-04-10 2025-10-16 Odyssey Therapeutics, Inc. Anti-tnfr2 antigen-binding proteins and uses thereof
US12459994B2 (en) 2024-04-12 2025-11-04 Paragon Therapeutics, Inc. Albumin binding proteins and methods of use
WO2025219231A1 (en) 2024-04-15 2025-10-23 Vib Vzw Computer-implemented means and methods for the de novo design of antibodies targeting a specific epitope
WO2025255558A2 (en) 2024-06-07 2025-12-11 Odyssey Therapeutics, Inc. Anti-thymic stromal lymphopoietin (tslp) antigen-binding proteins and uses thereof
WO2025255435A2 (en) 2024-06-07 2025-12-11 Odyssey Therapeutics, Inc. Antigen-binding proteins against serum albumin and uses thereof
US20260007757A1 (en) 2024-06-18 2026-01-08 Ablynx Nv Antibody-recruiting molecules
WO2026006809A1 (en) 2024-06-27 2026-01-02 Odyssey Therapeutics, Inc. Multispecific molecules binding tnfr2 and cd25 and uses thereof
WO2026006708A2 (en) 2024-06-27 2026-01-02 Odyssey Therapeutics, Inc. Anti-cd25 antigen-binding proteins and uses thereof
WO2026008664A1 (en) 2024-07-01 2026-01-08 Vib Vzw Allosteric modulators of inhibitory immune receptor complexes
WO2026024863A2 (en) 2024-07-24 2026-01-29 Amunix Pharmaceuticals, Inc. Compositions targeting prostate-specific membrane antigen (psma) in combination with androgen receptor antagonists

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1545106C3 (de) * 1963-07-16 1979-05-31 Union Carbide Corp., New York, N.Y. (V.St.A.) Verfahren zur Herstellung von linearen Polyarylenpolyäthern
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5248775A (en) 1989-12-11 1993-09-28 The Trustees Of Princeton University Pyrrolo(2,3-d)pyrimidines
KR0162654B1 (ko) 1989-12-11 1998-11-16 알렌 제이. 시니스갤리 N-(피롤로[2,3-d]피리미딘-3-일아크릴)-글루타민산 유도체
US5028608A (en) 1989-12-11 1991-07-02 The Trustees Of Princeton University N-(6-Amino-(pyrrolo(2,3-d)pyrimidin-3-ylacyl) )-glutamic acid derivatives
JP4124480B2 (ja) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
ATE420178T1 (de) 1992-08-21 2009-01-15 Univ Bruxelles Immunoglobuline ohne leichtkette
CA2321199A1 (en) 1998-02-19 1999-08-26 William A. Brady Compositions and methods for regulating lymphocyte activation
EP1141024B1 (en) 1999-01-15 2018-08-08 Genentech, Inc. POLYPEPTIDE COMPRISING A VARIANT HUMAN IgG1 Fc REGION
US7943129B2 (en) * 2000-05-26 2011-05-17 National Research Council Of Canada Single-domain brain-targeting antibody fragments derived from llama antibodies
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US20100081792A1 (en) 2001-06-28 2010-04-01 Smithkline Beecham Corporation Ligand
EP1412390A2 (en) 2001-07-26 2004-04-28 Tanox, Inc. Agents that activate or inhibit toll-like receptor 9
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
US20060002935A1 (en) 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
EP1600459A3 (en) 2002-06-28 2005-12-07 Domantis Limited Ligand
FR2846667B1 (fr) 2002-11-06 2004-12-31 Pasteur Institut Fragments variables d'anticorps de camelides a chaine unique diriges contre le peptide beta-amyloide 1-42 et leurs applications pour le diagnostic et le traitement des maladies neuroagregatives
JP2006520584A (ja) 2002-11-08 2006-09-14 アブリンクス エン．ヴェー． 安定化単一ドメイン抗体
AU2003286004A1 (en) 2002-11-08 2004-06-07 Ablynx N.V. Single domain antibodies directed against interferon- gamma and uses therefor
GB0230203D0 (en) 2002-12-27 2003-02-05 Domantis Ltd Fc fusion
WO2004062551A2 (en) 2003-01-10 2004-07-29 Ablynx N.V. RECOMBINANT VHH SINGLE DOMAIN ANTIBODY FROM CAMELIDAE AGAINST VON WILLEBRAND FACTOR (vWF) OR AGAINST COLLAGEN
EP1737890A2 (en) * 2004-03-24 2007-01-03 Xencor, Inc. Immunoglobulin variants outside the fc region
JP2008500830A (ja) 2004-06-01 2008-01-17 ドマンティス リミテッド 増加した血清半減期を有する二重特異性融合抗体
BRPI0518151A2 (pt) 2004-10-13 2009-06-16 Ablynx Nv polipetìdeos contra amiloide-beta, ácido nucléico que codifica tal polipetìdeo, composição compreendendo tal polipetìdeo, método para produzir um polipetìdeo e uso do mesmo
CA2588892A1 (en) 2004-12-02 2006-06-08 Dormantis Limited Anti-il-1r1 single domain antibodies and therapeutic uses
RU2428431C2 (ru) 2004-12-02 2011-09-10 Домантис Лимитед Слитые конструкции лекарственного средства и конъюгаты
EP3613767A1 (en) * 2005-05-18 2020-02-26 Ablynx N.V. Improved nanobodiestm against tumor cecrosis factor-alpha
KR101414438B1 (ko) 2005-05-20 2014-07-10 아블린쓰 엔.브이. 폰 빌레브란트 인자에 대한 단일 도메인 ｖｈｈ 항체
WO2006129843A2 (en) 2005-05-31 2006-12-07 Canon Kabushiki Kaisha Bispecific capturing molecule
PE20071101A1 (es) 2005-08-31 2007-12-21 Amgen Inc Polipeptidos y anticuerpos
JP2009519011A (ja) 2005-12-01 2009-05-14 ドマンティス リミテッド インターロイキン１受容体１型に結合する非競合ドメイン抗体フォーマット
CN101466734A (zh) 2005-12-01 2009-06-24 杜门蒂斯有限公司 与白细胞介素-1受体1型结合的竞争性域抗体形式
FR2894741B1 (fr) 2005-12-08 2009-12-04 Centre Nat Etd Spatiales Chaine de reception par satellite
CA2640066A1 (en) 2006-01-24 2007-08-02 Roland Beckmann Fusion proteins that contain natural junctions
JP2010500876A (ja) 2006-08-18 2010-01-14 アブリンクス エン．ヴェー． Ｉｌ−６媒介性シグナル伝達に関連する疾患及び障害の治療のための、ｉｌ−６ｒに指向性を有するアミノ酸配列及びこれを含むポリペプチド
JP2010511397A (ja) 2006-12-05 2010-04-15 アブリンクス エン．ヴェー． 血清タンパク質と結合可能なペプチド
AU2007331672A1 (en) 2006-12-15 2008-06-19 Ablynx N.V. Amino acid sequences that modulate the interaction between cells of the immune system
CN101796072B (zh) 2007-05-24 2014-09-24 埃博灵克斯股份有限公司 用于治疗骨疾病和病症的针对rank-l的氨基酸序列以及包括其的多肽
NZ581468A (en) * 2007-06-25 2012-09-28 Esbatech Alcon Biomed Res Unit Methods of modifying antibodies, and modified antibodies with improved functional properties
AU2008328781A1 (en) 2007-11-27 2009-06-04 Ablynx N.V. Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same
WO2009121804A1 (en) 2008-03-31 2009-10-08 Glaxo Group Limited Drug fusions and conjugates
EP2268668A1 (en) 2008-04-17 2011-01-05 Ablynx N.V. Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same
WO2009138494A2 (en) * 2008-05-15 2009-11-19 Ablynx N.V. Amino acid sequences directed against toll-like receptors and polypeptides comprising the same for the treatment of diseases related to toll-like receptors
DE102008023620A1 (de) 2008-05-15 2009-11-19 Mettler-Toledo (Albstadt) Gmbh Funktionseinheit mit einer aufrufbaren Funktion und Verfahren zu deren Aufruf
BRPI0911984A2 (pt) 2008-05-16 2016-09-20 Ablynx Nv sequências de aminoácidos direncionadas contra cxcr4 e outros compostos gpcrs compreendendo os mesmos
EP2143735A1 (en) * 2008-07-10 2010-01-13 Institut Pasteur Variable domains of camelid heavy-chain antibodies directed against glial fibrillary acidic proteins
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
WO2010042815A2 (en) 2008-10-09 2010-04-15 Duke University Vhh antibody fragments for use in the detection and treatment of cancer
NZ595344A (en) 2009-03-27 2013-09-27 Glaxo Group Ltd Drug fusions and conjugates
EP3828201A1 (en) 2009-04-30 2021-06-02 Ablynx N.V. Method for the production of domain antibodies
WO2010130832A2 (en) 2009-05-15 2010-11-18 Ablynx N.V. Amino acid sequences directed against dickkopf-1 and polypeptides comprising the same for the treatment of diseases and disorders associated with bone loss and/or osteolytic lesions
EP2435480A1 (en) 2009-05-27 2012-04-04 Ablynx N.V. Biparatopic protein constructs directed against il-23
CN102458471A (zh) 2009-05-28 2012-05-16 葛兰素集团有限公司 用于治疗或预防眼病的TNFα拮抗剂和VEGF拮抗剂的组合
US9150640B2 (en) 2009-07-10 2015-10-06 Ablynx N.V. Method for the production of variable domains
US8306355B2 (en) 2009-07-13 2012-11-06 Sharp Laboratories Of America, Inc. Methods and systems for reducing compression artifacts
WO2011042398A1 (en) 2009-10-09 2011-04-14 Ablynx Nv Immunoglobulin single variable domain directed against human cxcr4 and other cell associated proteins and methods to generate them
US8962807B2 (en) * 2009-12-14 2015-02-24 Ablynx N.V. Single variable domain antibodies against OX40L, constructs and therapeutic use
CA2777527C (en) 2009-12-23 2020-06-23 Esbatech, An Alcon Biomedical Research Unit Llc Method for decreasing immunogenicity
CA2788275A1 (en) 2010-03-03 2011-09-09 Boehringer Ingelheim International Gmbh Biparatopic abeta binding polypeptides
WO2011117423A1 (en) 2010-03-26 2011-09-29 Ablynx N.V. Immunoglobulin single variable domains directed against cxcr7
AU2011247612A1 (en) 2010-04-30 2012-12-06 Ablynx Nv Amino acid sequences of nanobodies directed against p19 subunit of the heterodimeric cytokine IL-23
EP3546483A1 (en) 2010-05-20 2019-10-02 Ablynx N.V. Biological materials related to her3
WO2011161266A1 (en) 2010-06-25 2011-12-29 Ablynx Nv Improved immunoglobulin single variable domains and constructs thereof directed against cxcr4
JP2013145769A (ja) 2010-08-04 2013-07-25 Kri Inc 異方性希土類ボンド磁石とその製造方法
EP2621953B1 (en) 2010-09-30 2017-04-05 Ablynx N.V. Biological materials related to c-met
WO2012104227A1 (en) 2011-02-02 2012-08-09 Glaxo Group Limited Novel antigen binding proteins
JP6181040B2 (ja) 2011-03-28 2017-08-16 アブリンクス エン．ヴェー． 二特異性抗ｃｘｃｒ７免疫グロブリン単一可変ドメイン
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
WO2012175740A1 (en) 2011-06-23 2012-12-27 Ablynx Nv Immunoglobulin single variable domains directed against ige
SI2723771T1 (sl) 2011-06-23 2019-12-31 Ablynx Nv Proteini, ki vežejo serum albumin
SG10201605048XA (en) 2011-06-23 2016-07-28 Ablynx Nv Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
US20130019175A1 (en) 2011-07-14 2013-01-17 Microsoft Corporation Submenus for context based menu system
TW201321405A (zh) * 2011-08-17 2013-06-01 Glaxo Group Ltd 經修飾之蛋白質及肽
JP6219287B2 (ja) 2011-09-30 2017-10-25 アブリンクス エン．ヴェー． ｃ−Ｍｅｔに関連する生物学的物質
LT2627773T (lt) 2011-10-17 2017-12-27 Regeneron Pharmaceuticals, Inc. Pelės iškirpta sunkioji imunoglobulino grandinė
US20130129727A1 (en) 2011-11-17 2013-05-23 Nanjingjinsirui Science & Technology Biology Corporation Methods and systems for increasing protein stability
WO2013116296A1 (en) * 2012-01-31 2013-08-08 Regeneron Pharmaceuticals, Inc. Anti-asic1 antibodies and uses thereof
JP6608698B2 (ja) 2012-06-01 2019-11-27 アブリンクス エン．ヴェー． Ｐ２ｘ７受容体アンタゴニスト及びアゴニスト
TWI641619B (zh) 2012-06-25 2018-11-21 美商再生元醫藥公司 抗－ｅｇｆｒ抗體及其用途
EP2895510A2 (en) * 2012-09-13 2015-07-22 Novartis AG Single domain antibody with c-terminal modification
US9667316B2 (en) 2013-05-17 2017-05-30 The Boeing Company Aircraft data transmission using phase separation
AU2015261536B2 (en) 2014-05-16 2020-05-07 Ablynx Nv Improved immunoglobulin variable domains
RU2018119732A (ru) 2015-10-30 2019-12-03 Аблинкс Нв Полипептиды против il-23
JP7403224B2 (ja) 2015-11-12 2023-12-22 アブリンクス エン．ヴェー． 改良されたｐ２ｘ７受容体結合剤およびこれを含むポリペプチド
NO2768984T3 (es) 2015-11-12 2018-06-09
RS62857B1 (sr) 2015-11-13 2022-02-28 Ablynx Nv Unapređeni varijabilni domeni imunoglobulina koji vezuju serumski albumin
JP7046804B2 (ja) 2015-11-18 2022-04-04 アブリンクス エン．ヴェー． 改良された血清アルブミン結合剤
EA038179B1 (ru) 2015-11-18 2021-07-20 Мерк Шарп И Доум Корп. Ctla4-связывающие вещества
UA121914C2 (uk) 2015-11-18 2020-08-10 Мерк Шарп І Доум Корп. Молекула, що зв'язує pd1 і lag3
RU2755724C2 (ru) 2015-11-18 2021-09-20 Мерк Шарп И Доум Корп. Pd1/ctla4-связывающие вещества
SG10202108973SA (en) 2017-01-17 2021-09-29 Ablynx Nv Improved serum albumin binders
WO2021110816A1 (en) 2019-12-06 2021-06-10 Ablynx Nv POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING TNFα AND IL-23
AR120698A1 (es) 2019-12-09 2022-03-09 Ablynx Nv Polipéptidos que comprenden dominios variables únicos de inmunoglobulina que se dirigen a il-13 y tslp
TW202239763A (zh) 2020-12-18 2022-10-16 比利時商艾伯霖克斯公司 包含靶向ＩＬ－６和ＴＮＦ－α的免疫球蛋白單可變結構域的多肽

Also Published As

Publication number Publication date
MX383560B (es) 2025-03-14
CA3175002A1 (en) 2015-11-19
AU2018204226A1 (en) 2018-07-05
IL299282B2 (en) 2024-09-01
AU2020202855A1 (en) 2020-05-21
RU2018120744A3 (es) 2022-01-28
IL295534B2 (en) 2025-03-01
US20210261653A1 (en) 2021-08-26
US11312764B2 (en) 2022-04-26
US12180268B2 (en) 2024-12-31
RU2021107470A (ru) 2021-05-17
US20220332807A1 (en) 2022-10-20
IL281755A (en) 2021-05-31
DK3248986T3 (da) 2022-04-04
IL248636A0 (en) 2017-01-31
RU2746738C2 (ru) 2021-04-20
ZA202004759B (en) 2022-08-31
SI3143042T1 (sl) 2020-08-31
IL311293B2 (en) 2025-07-01
US11319364B2 (en) 2022-05-03
PT3248986T (pt) 2022-04-05
US20210087261A1 (en) 2021-03-25
SG10201810124PA (en) 2018-12-28
IL259972B (en) 2021-04-29
SG11201609162SA (en) 2016-12-29
CN109053885A (zh) 2018-12-21
IL281755B1 (en) 2023-01-01
NZ726448A (en) 2023-02-24
HRP20200966T1 (hr) 2020-10-16
HUE050007T2 (hu) 2020-11-30
JP2024041939A (ja) 2024-03-27
IL299282B1 (en) 2024-05-01
CN106661100A (zh) 2017-05-10
IL311293A (en) 2024-05-01
JP2021130681A (ja) 2021-09-09
AU2022279374B2 (en) 2026-01-15
US20210269514A1 (en) 2021-09-02
KR102827683B1 (ko) 2025-06-30
MX2023010731A (es) 2023-09-20
US20200231662A1 (en) 2020-07-23
EP3693386A1 (en) 2020-08-12
ZA202100742B (en) 2022-09-28
EP3248986B1 (en) 2022-01-26
JP7471987B2 (ja) 2024-04-22
PH12016502282B1 (en) 2024-05-22
RU2016149463A (ru) 2018-06-19
US11312765B2 (en) 2022-04-26
US20220135657A9 (en) 2022-05-05
HRP20220400T1 (hr) 2022-05-27
EP3143042B1 (en) 2020-06-10
AU2022279374A1 (en) 2023-01-19
ES2815572T3 (es) 2021-03-30
BR112016026773A2 (pt) 2017-12-12
US11220539B2 (en) 2022-01-11
KR20170002645A (ko) 2017-01-06
PL3248986T3 (pl) 2022-05-16
ZA201607587B (en) 2022-05-25
US20220119512A1 (en) 2022-04-21
AU2020202855B2 (en) 2022-12-08
RU2016149463A3 (es) 2018-07-04
ZA202004757B (en) 2022-08-31
EP3702369A1 (en) 2020-09-02
HUE058008T2 (hu) 2022-06-28
US20220251183A1 (en) 2022-08-11
IL295534A (en) 2022-10-01
KR20230145503A (ko) 2023-10-17
CA2948076A1 (en) 2015-11-19
SI3248986T1 (sl) 2022-04-29
US11708404B2 (en) 2023-07-25
MX2018007581A (es) 2020-11-12
LT3143042T (lt) 2020-07-27
RU2018120744A (ru) 2018-11-15
JP7325928B2 (ja) 2023-08-15
IL259972A (en) 2018-07-31
RS63085B1 (sr) 2022-04-29
EP3248986A2 (en) 2017-11-29
JP2017518072A (ja) 2017-07-06
AU2015261536B2 (en) 2020-05-07
AU2022279373A1 (en) 2023-01-19
JP2024069377A (ja) 2024-05-21
JP2018162297A (ja) 2018-10-18
PL3143042T3 (pl) 2020-11-16
SG10201805288QA (en) 2018-07-30
IL281755B2 (en) 2023-05-01
US20170121399A1 (en) 2017-05-04
LT3248986T (lt) 2022-03-25
JP2021006563A (ja) 2021-01-21
ES2912069T3 (es) 2022-05-24
RS60717B1 (sr) 2020-09-30
WO2015173325A2 (en) 2015-11-19
US11485777B2 (en) 2022-11-01
AU2020202570B2 (en) 2022-12-08
KR102769509B1 (ko) 2025-02-17
PT3143042T (pt) 2020-09-01
KR20180091115A (ko) 2018-08-14
DK3143042T3 (da) 2020-08-31
US20220332806A1 (en) 2022-10-20
AU2015261536A1 (en) 2016-11-17
US11485778B2 (en) 2022-11-01
CN113717280A (zh) 2021-11-30
ZA202004758B (en) 2022-08-31
IL295534B1 (en) 2024-11-01
EP3143042A2 (en) 2017-03-22
KR20230053002A (ko) 2023-04-20
IL299282A (en) 2023-02-01
JP7454525B2 (ja) 2024-03-22
IL311293B1 (en) 2025-03-01
JP7098439B2 (ja) 2022-07-11
MX2021007020A (es) 2021-08-05
KR20230054503A (ko) 2023-04-24
EP3248986A3 (en) 2017-12-20
US20210269515A1 (en) 2021-09-02
IL248636B2 (en) 2023-04-01
WO2015173325A8 (en) 2016-12-29
PH12016502282A1 (en) 2017-02-13
IL248636B (en) 2022-12-01
AU2020202570A1 (en) 2020-05-07
WO2015173325A3 (en) 2016-02-18
BR122018009619B1 (pt) 2024-01-02

Similar Documents

Publication Publication Date Title
MX2016014926A (es) Dominios variables de inmunoglobulina mejorados.
CY1124215T1 (el) Μκ2 αναστολεις και χρησεις αυτων
MX2022005202A (es) Anticuerpos anti-promiostatina o miostatina latente y usos de los mismos.
JOP20190194B1 (ar) مركبات نيوكليوتيدات ثنائية حلقية لعلاج السرطان
PE20170908A1 (es) VARIANTES DE INTERFERON a2b
BR112017009467A2 (pt) composição de limpeza
EA201790173A1 (ru) Антитела, связывающие axl
CL2017001883A1 (es) Compuestos antisenescentes y usos de los mismos
CL2017002452A1 (es) Nuevos compuestos bicíclicos
EA201792307A1 (ru) Способы репарации и регенерации тканей
PE20170471A1 (es) Polipeptidos receptores formulados y metodos relacionados
EA201790505A1 (ru) Соединение, нацеленое на ил-23а и фно-альфа, и его применение
MX378238B (es) Moléculas de unión con dominios de fibronectina de tipo iii modificadas con cisteína.
ES2693321T3 (es) Péptidos antiinflamatorios y composición que comprende los mismos
CR20160418A (es) Nuevos compuestos biciclicos de 7 eslabones
BR112016024494A8 (pt) análogo de peptídeo e seu uso
PH12016501937A1 (en) Method for improving solubility of protein and peptide by using immunoglobulin fc fragment linkage
EA201691429A1 (ru) МОДИФИЦИРОВАННЫЕ МЕНИНГОКОККОВЫЕ ПОЛИПЕПТИДЫ fHbp
DOP2018000284A (es) Anticuerpos antifactor de la coagulación xi
BR112019000135A2 (pt) formulações de anticorpo
EA201692028A1 (ru) Применение замещенных оксотетрагидрохинолинилсульфонамидов или их солей для повышения стрессоустойчивости растений
PH12019502075A1 (en) A liquid formulation of anti-tnf alpha antibody
BR112018003714A2 (pt) composições de ácido de peso aumentado que compreendem aminoácidos
WO2014152831A3 (en) Targeting peptides and uses thereof
MX2017003949A (es) Derivados peptidicos novedosos y sus usos.